Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS05)

Next Previous
Trial Profile

Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS05)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms AMS05

Most Recent Events

  • 02 Mar 2024 Results assessing the the rate of durable remission of relapsing disease activity using frequent serial clinical and MRI assessments through 48 months, in participants with early RMS who discontinue the aCD20 ocrelizumab (OCR) after 12 or 24 months of treatment, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024.
  • 13 Oct 2023 Target enrollment is175 participants with the goal to randomize 150 participantsacross the 3 treatment arms, as per trial design presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
  • 13 Oct 2023 Trial design presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top